GSA Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $701K | Buy |
+1,570
| New | +$732K | 0.04% | 704 |
|
|
2025
Q4 | – | Sell |
-569
| Closed | -$223K | – | 2125 |
|
|
2025
Q3 | $223K | Sell |
569
-1,002
| -64% | -$419K | 0.02% | 1375 |
|
|
2025
Q2 | $699K | Buy |
1,571
+837
| +114% | +$386K | 0.05% | 690 |
|
|
2025
Q1 | $356K | Sell |
734
-1,255
| -63% | -$585K | 0.03% | 1033 |
|
|
2024
Q4 | $801K | Buy |
+1,989
| New | +$922K | 0.06% | 559 |
|
|
2024
Q3 | – | Sell |
-652
| Closed | -$306K | – | 2039 |
|
|
2024
Q2 | $306K | Buy |
+652
| New | +$283K | 0.02% | 1275 |
|
|
2022
Q3 | – | Sell |
-1,670
| Closed | -$471K | – | 1894 |
|
|
2022
Q2 | $471K | Sell |
1,670
-1,743
| -51% | -$467K | 0.07% | 542 |
|
|
2022
Q1 | $891K | Buy |
3,413
+1,849
| +118% | +$439K | 0.12% | 225 |
|
|
2021
Q4 | $343K | Sell |
1,564
-895
| -36% | -$174K | 0.04% | 849 |
|
|
2021
Q3 | $446K | Buy |
2,459
+1,372
| +126% | +$268K | 0.05% | 764 |
|
|
2021
Q2 | $219K | Buy |
+1,087
| New | +$227K | 0.02% | 1138 |
|
|
2020
Q4 | – | Sell |
-1,037
| Closed | -$282K | – | 1634 |
|
|
2020
Q3 | $282K | Buy |
+1,037
| New | +$286K | 0.05% | 785 |
|
|
2020
Q2 | – | Sell |
-1,490
| Closed | -$355K | – | 1140 |
|
|
2020
Q1 | $355K | Sell |
1,490
-1,077
| -42% | -$247K | 0.09% | 373 |
|
|
2019
Q4 | $562K | Sell |
2,567
-7,105
| -73% | -$1.44M | 0.07% | 576 |
|
|
2019
Q3 | $1.64M | Buy |
9,672
+7,479
| +341% | +$1.32M | 0.22% | 36 |
|
|
2019
Q2 | $402K | Sell |
2,193
-2,002
| -48% | -$350K | 0.05% | 803 |
|
|
2019
Q1 | $772K | Sell |
4,195
-417
| -9% | -$77K | 0.08% | 438 |
|
|
2018
Q4 | $764K | Sell |
4,612
-7,743
| -63% | -$1.34M | 0.09% | 341 |
|
|
2018
Q3 | $2.38M | Sell |
12,355
-9,087
| -42% | -$1.62M | 0.13% | 173 |
|
|
2018
Q2 | $3.64M | Sell |
21,442
-12,129
| -36% | -$1.88M | 0.18% | 69 |
|
|
2018
Q1 | $5.47M | Buy |
33,571
+7,264
| +28% | +$1.19M | 0.29% | 17 |
|
|
2017
Q4 | $3.94M | Buy |
26,307
+9,194
| +54% | +$1.36M | 0.24% | 33 |
|
|
2017
Q3 | $2.6M | Sell |
17,113
-1,910
| -10% | -$287K | 0.18% | 82 |
|
|
2017
Q2 | $2.45M | Buy |
19,023
+11,523
| +154% | +$1.39M | 0.16% | 100 |
|
|
2017
Q1 | $820K | Sell |
7,500
-31,692
| -81% | -$2.79M | 0.04% | 771 |
|
|
2016
Q4 | $2.89M | Buy |
39,192
+22,369
| +133% | +$1.82M | 0.17% | 91 |
|
|
2016
Q3 | $1.47M | Buy |
16,823
+14,156
| +531% | +$1.34M | 0.08% | 385 |
|
|
2016
Q2 | $229K | Sell |
2,667
-45,339
| -94% | -$3.92M | 0.01% | 1513 |
|
|
2016
Q1 | $3.82M | Buy |
+48,006
| New | +$4.34M | 0.24% | 29 |
|
|
2015
Q4 | – | Sell |
-49,171
| Closed | -$5.12M | – | 1983 |
|
|
2015
Q3 | $5.12M | Buy |
49,171
+35,079
| +249% | +$4.51M | 0.25% | 42 |
|
|
2015
Q2 | $1.74M | Buy |
14,092
+7,118
| +102% | +$897K | 0.07% | 482 |
|
|
2015
Q1 | $823K | Sell |
6,974
-4,756
| -41% | -$570K | 0.03% | 1024 |
|
|
2014
Q4 | $1.39M | Buy |
+11,730
| New | +$1.32M | 0.1% | 281 |
|
|
2014
Q2 | – | Sell |
-76,548
| Closed | -$5.41M | – | 1975 |
|
|
2014
Q1 | $5.41M | Buy |
+76,548
| New | +$6.06M | 0.39% | 37 |
|
|
2013
Q4 | – | Sell |
-23,055
| Closed | -$1.75M | – | 1782 |
|
|
2013
Q3 | $1.75M | Sell |
23,055
-643
| -3% | -$51.2K | 0.14% | 148 |
|
|
2013
Q2 | $1.9M | Buy |
+23,698
| New | +$1.75M | 0.23% | 74 |
|
Other funds holding VRTX
VCM
VPM
GSA Capital Partners's VRTX Position: Q1 2026 in Review
GSA Capital Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 1,570 shares worth $701K. The stake represents 0.04% of the portfolio and ranks #704 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in VRTX as recently as Q3 2025.
GSA Capital Partners first reported a position in VRTX in Q2 2013 and has held it in 36 quarters since. The position peaked at $5.47M in Q1 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- GSA Capital Partners held 1,570 shares of Vertex Pharmaceuticals worth $701K as of Q1 2026.
- Vertex Pharmaceuticals was a new GSA Capital Partners position in Q1 2026.
- Vertex Pharmaceuticals made up 0.04% of GSA Capital Partners's portfolio in Q1 2026, its #704 holding.
- GSA Capital Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
- GSA Capital Partners's Vertex Pharmaceuticals position peaked at $5.47M in Q1 2018.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.